Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danielle Antin-Ozerkis

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Clinics in Chest Medicine|August 5, 2019
Connective Tissue Disease-Associated Interstitial Lung Disease: Evaluation and ManagementDanielle Antin-Ozerkis, Monique Hinchcliff
Seminars in Respiratory and Critical Care Medicine|March 27, 2014
Supportive care for patients with pulmonary complications of connective tissue diseaseMridu Gulati, Danielle Antin-Ozerkis
Chest|May 9, 2021
An 84-Year-Old Physician With Progressive Dyspnea and Bilateral Upper Lobe OpacitiesZachary M Harris, Danielle Antin-Ozerkis
The Laryngoscope|October 12, 2004
Laryngeal findings in users of combination corticosteroid and bronchodilator therapyNatasha Mirza, Sandra Kasper Schwartz, Danielle Antin-Ozerkis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a reviewSunil Singhal, Anil Vachani, Danielle Antin-Ozerkis, et al.
Clinics in Chest Medicine|August 10, 2010
Pulmonary manifestations of rheumatoid arthritisDanielle Antin-Ozerkis, Janine Evans, Ami Rubinowitz, et al.
Clinics in Chest Medicine|February 28, 2012
Interstitial lung disease in the connective tissue diseasesDanielle Antin-Ozerkis, Ami Rubinowitz, Janine Evans, et al.
Pulmonary Therapy|February 7, 2020
An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)Mark H Gotfried, Carlos E Girod, Danielle Antin-Ozerkis, et al.
Lung|January 9, 2025
Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ONWim A Wuyts, Francesco Bonella, Nazia Chaudhuri, et al.
Respiratory Medicine|April 10, 2019
Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trialsWim Wuyts, Danielle Antin-Ozerkis, J Terrill Huggins, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Clinics in Chest Medicine|August 5, 2019
Connective Tissue Disease-Associated Interstitial Lung Disease: Evaluation and ManagementDanielle Antin-Ozerkis, Monique Hinchcliff
Seminars in Respiratory and Critical Care Medicine|March 27, 2014
Supportive care for patients with pulmonary complications of connective tissue diseaseMridu Gulati, Danielle Antin-Ozerkis
Chest|May 9, 2021
An 84-Year-Old Physician With Progressive Dyspnea and Bilateral Upper Lobe OpacitiesZachary M Harris, Danielle Antin-Ozerkis
The Laryngoscope|October 12, 2004
Laryngeal findings in users of combination corticosteroid and bronchodilator therapyNatasha Mirza, Sandra Kasper Schwartz, Danielle Antin-Ozerkis
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a reviewSunil Singhal, Anil Vachani, Danielle Antin-Ozerkis, et al.
Clinics in Chest Medicine|August 10, 2010
Pulmonary manifestations of rheumatoid arthritisDanielle Antin-Ozerkis, Janine Evans, Ami Rubinowitz, et al.
Clinics in Chest Medicine|February 28, 2012
Interstitial lung disease in the connective tissue diseasesDanielle Antin-Ozerkis, Ami Rubinowitz, Janine Evans, et al.
Pulmonary Therapy|February 7, 2020
An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)Mark H Gotfried, Carlos E Girod, Danielle Antin-Ozerkis, et al.
Lung|January 9, 2025
Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ONWim A Wuyts, Francesco Bonella, Nazia Chaudhuri, et al.
Respiratory Medicine|April 10, 2019
Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trialsWim Wuyts, Danielle Antin-Ozerkis, J Terrill Huggins, et al.
Pageof 2